Hepatitis B Clinical Trials

Find Hepatitis B Clinical Trials Near You

Adaptability of an Undetectable = Untransmissible Model for HBV: Are Suppressed Viral Levels in the Serum Consistent Across Body Fluid Reservoirs?

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Persons with chronic hepatitis B (HBV) infection and active viremia are infectious and may transmit virus to others through blood/body fluid exposure. Immune tolerant treatment naive persons with hepatitis B infection express anxiety regarding disclosure of their infection status and significant fear of transmission to their partners leading to social isolation and impact on their personal lives. This study will provide data correlating serum and body fluid viral levels in persons with chronic hepatitis B infection not on therapy and those with viral suppression on long-term anti-retroviral therapy (ART) that may support the concept of Undetectable=Untransmissible (U=U) in patients with chronic hepatitis B.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:

∙ Infected Individuals

• Individuals above 18 years and less than 65 years with chronic hepatitis B infection

• Included according to undermentioned three arms:

‣ Infected, On-treatment arm: subjects being treated with TAF/TDF for a minimum of 2 years with sustained viral suppression indicating adherence to therapy

⁃ Infected, Untreated control arm: Immune tolerant subjects; 15 with high viral load (\>10\^6) and 5 with low viral load (\<10\^6)

⁃ Uninfected Assay Validation controls: 10 subjects with history of prior infection who have convalesced i.e., have lost surface antigen, and developed surface antibody with viral eradication

• Able and willing to provide informed consent

∙ Healthy Controls

• Individuals above 18 years and less than 65 years who have never been infected and have been vaccinated

• Able and willing to provide informed consent

Locations
United States
New York
NYU Langone Health
RECRUITING
New York
Contact Information
Primary
AnnMarie Liapakis, MD
AnnMarie.Liapakis@nyulangone.org
212-263-3751
Time Frame
Start Date: 2026-05-01
Estimated Completion Date: 2027-09
Participants
Target number of participants: 55
Treatments
Anti-Viral Therapy
Infected individuals on anti-viral therapy.
No Therapy
Infected individuals who are not receiving anti-viral therapy.
Convalesced
Individuals who have cleared HBV infection.
Healthy Controls
Individuals who are uninfected.
Related Therapeutic Areas
Sponsors
Leads: NYU Langone Health
Collaborators: Gilead Sciences

This content was sourced from clinicaltrials.gov